Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
Pfizer will present over 40 abstracts at ASCO 2026, featuring late-breaking Phase 3 data for key assets like BRAFTOVI in colorectal cancer and TALZENNA plus XTANDI in prostate cancer. The data set includes a seven-year update for LORBRENA in lung cancer and early-stage results for next-generation pipeline candidates such as sigvotatug vedotin and PF-08634404.
Key figures
- Drug Name
- LORBRENA, BRAFTOVI, TALZENNA, XTANDI, TUKYSA, sigvotatug vedotin, PF-08634404, atirmociclib, PF-07799544, PF-07799933, elranatamab
- Phase Of Trial
- Phase 1, Phase 1b, Phase 2, Phase 3
- Oral presentations
- 8
- Abstracts presented
- 40+
- Late breaking sessions
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.